A Comparative Study of Levocetirizine Loaded Vesicular and Matrix Type System for Topical Application: Appraisal of Therapeutic Potential against Atopic Dermatitis

Pal, Ravi Raj; Maurya, Anish Kumar; Parashar, Poonam; Saraf, Shubhini A.

doi:10.1007/s12247-020-09465-x

Cited by 12 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many drugs do not reach the antineoplastic drug pipeline because of low aqueous solubility, high toxicity, large doses, and shorter half-life. Nanoformualtions provide opportunities to improve the pharmacokinetics of these drugs for precise treatment at the molecular level with reduced off-target effect [ 164 , 165 ]. The tumor tissues that exhibit enhanced permeability and retention (EPR) and hypoxia-like properties could be utilized for targeted drug delivery.…”

Section: Neoplasm and Its Pathogenesismentioning

confidence: 99%

Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Cancer causes a considerable amount of mortality in the world, while arthritis is an immunological dysregulation with multifactorial pathogenesis including genetic and environmental defects. Both conditions have inflammation as a part of their pathogenesis. Resistance to anticancer and disease-modifying antirheumatic drugs (DMARDs) happens frequently through the generation of energy-dependent transporters, which lead to the expulsion of cellular drug contents. Thymoquinone (TQ) is a bioactive molecule with anticancer as well as anti-inflammatory activities via the downregulation of several chemokines and cytokines. Nevertheless, the pharmacological importance and therapeutic feasibility of thymoquinone are underutilized due to intrinsic pharmacokinetics, including short half-life, inadequate biological stability, poor aqueous solubility, and low bioavailability. Owing to these pharmacokinetic limitations of TQ, nanoformulations have gained remarkable attention in recent years. Therefore, this compilation intends to critically analyze recent advancements in rheumatoid arthritis and cancer delivery of TQ. This literature search revealed that nanocarriers exhibit potential results in achieving targetability, maximizing drug internalization, as well as enhancing the anti-inflammatory and anticancer efficacy of TQ. Additionally, TQ-NPs (thymoquinone nanoparticles) as a therapeutic payload modulated autophagy as well as enhanced the potential of other drugs when given in combination. Moreover, nanoformulations improved pharmacokinetics, drug deposition, using EPR (enhanced permeability and retention) and receptor-mediated delivery, and enhanced anti-inflammatory and anticancer properties. TQ’s potential to reduce metal toxicity, its clinical trials and patents have also been discussed.

show abstract

Section: Neoplasm and Its Pathogenesismentioning

confidence: 99%

Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Finally, the skin sample was embedded in paraffin, cut into fine slices, and treated with hematoxylin and eosin for staining before observing under a light microscope at 40X. The results were compared with those of the untreated rat skin. , …”

Section: Methodsmentioning

confidence: 99%

“…16 The pharmacological activity shows that levocetirizine is capable of modifying allergic mediators that are produced by eosinophils such as cytokines, antiproteinases, and growth factor. 17 The study performed suggested that levocetirizine reduces the expression of IL-5 in CD4+ cells and IL-13 in CD4+ and CD8+ cells. Moreover, it enhances the expression of IL-10 in CD4+ cells.…”

Section: Introductionmentioning

confidence: 95%

“…Levocetirizine dihydrochloride is an enantiomeric derivative of cetirizine possessing antihistaminic activity toward various allergic mediators . The pharmacological activity shows that levocetirizine is capable of modifying allergic mediators that are produced by eosinophils such as cytokines, antiproteinases, and growth factor . The study performed suggested that levocetirizine reduces the expression of IL-5 in CD4+ cells and IL-13 in CD4+ and CD8+ cells.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dual Delivery of Fluticasone Propionate and Levocetirizine Dihydrochloride for the Management of Atopic Dermatitis Using a Microemulsion-Based Topical Gel

et al. 2022

View full text Add to dashboard Cite

The current study investigates the potential for topical delivery of a fluticasone propionate (FP) and levocetirizine dihydrochloride (CTZ)-loaded microemulsion (ME) for the management of atopic dermatitis. Various microemulsion components were chosen based on their solubility and emulsification capabilities, and the ternary phase diagram was constructed. A total of 12 microemulsion formulations were screened for various attributes like vesicle size, polydispersity index, ζ-potential, percent transmittance, density, and pH. The average globule size and ζ-potential of FP and levocetirizine-containing ME were 52.12 nm and −2.98 ζ-potential, respectively. Transmission electron microscopy confirmed the spherical nature of the globules. The developed system not only controlled the release of both drugs but also enhanced the efficacy of the drugs on a rodent model. Histopathological studies confirmed the safety of the developed system. The present findings provide evidence for a scalable and simpler approach for the management of atopic dermatitis.

show abstract

Bridging Bio-Nanoscience and Cancer Nanomedicine

Alka

Nisha

Singh

et al. 2022

Pharmacokinetics and Pharmacodynamics of Nanoparticulate Drug Delivery Systems

View full text Add to dashboard Cite

A Comparative Study of Levocetirizine Loaded Vesicular and Matrix Type System for Topical Application: Appraisal of Therapeutic Potential against Atopic Dermatitis

Cited by 12 publications

References 38 publications

Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

Recent Findings on Thymoquinone and Its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

Dual Delivery of Fluticasone Propionate and Levocetirizine Dihydrochloride for the Management of Atopic Dermatitis Using a Microemulsion-Based Topical Gel

Bridging Bio-Nanoscience and Cancer Nanomedicine

Contact Info

Product

Resources

About